Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review

References

• Pande M, Debanjan Kundu RS. Drugs repurposing against SARS-CoV2 and the new variant B.1.1.7 (Alpha Strain) targeting the spike protein: molecular docking and Simulation studies. Estuar Coast Shelf Sci. 2021;7:107397. doi:10.1016/j.heliyon.2021.e07803
   Google Scholar
• Das A, Roy S, Swarnakar S, Chatterjee N. Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: a therapeutic approach. Clin Immunol. 2021;231:108804. doi:10.1016/j.clim.2021.108804
   PubMed Web of Science ®Google Scholar
• Manta B, Sarkisian AG. Fisiopatología de la enfermedad COVID-19. Odontoestomatologia. 2022;24:1–19. doi:10.22592/ode2022n39e312
   Google Scholar
• Jessie H, Hume AJ, Abo KM, et al. SARS-CoV-2 infection of pluripotent stem cell- derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Ann Oncol. 2020;110:19–21.
   Google Scholar
• Zhu Y, Sharma L, Chang D. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review. Front Immunol. 2023;14(August):1–13. doi:10.3389/fimmu.2023.1116131
   Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. doi:10.1038/s41591-020-0968-3
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xiang R, Huo S, et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther. 2021;6(1). doi:10.1038/s41392-021-00653-w
   Web of Science ®Google Scholar
• Malone B, Urakova N, Snijder EJ, Campbell EA. Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol. 2022;23(1):21–39. doi:10.1038/s41580-021-00432-z
   PubMed Web of Science ®Google Scholar
• V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–170. doi:10.1038/s41579-020-00468-6
   PubMed Web of Science ®Google Scholar
• Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronav Dis. 2020;2:23–31. doi:10.1007/978-981-15-4814-7_3
   Google Scholar
• BBC NEWS. Cifras de la pandemia país por país [Pandemic figures country by country]; 2021. Available from: https://www.bbc.com/mundo/noticias-51705060. Accessed September 6, 2021.
   Google Scholar
• Farooqi T, Ahmad Malik J, Hanif Mulla A, et al. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. Carbohydr Polym. 2019;115800. doi:10.1016/j.jiph.2021.08.014
   PubMedGoogle Scholar
• Srivastava V, Ahmad A. New perspective towards therapeutic regimen against SARS-CoV-2 infection. J Infect Public Health. 2021;14(7):852–862. doi:10.1016/j.jiph.2021.05.009
   PubMed Web of Science ®Google Scholar
• Muhammed Y, Yusuf A, Pius M, et al. SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: a review. Biosaf Health. 2021;3(5):249–263. doi:10.1016/j.bsheal.2021.07.003
   PubMedGoogle Scholar
• Covid: qué son baricitinib y sotrovimab, los nuevos medicamentos que autorizó la OMS para tratar casos de la enfermedad [COVID: what are baricitinib and sotrovimab, the new drugs authorized by the WHO to treat cases of the disease]. BBC News Mundo. Available from: https://www.bbc.com/mundo/noticias-60058017. Accessed January 22, 2022
   Google Scholar
• Matrose NA, Obikese K, Belay ZA, Caleb OJ. Drug repurposing against coronavirus disease 2019 (COVID-19): a review. Sci Total Environ. 2021;135907. doi:10.1016/j.jpha.2021.09.001
   Google Scholar
• Aronskyy I, Masoudi-Sobhanzadeh Y, Cappuccio A, Zaslavsky E. Advances in the computational landscape for repurposed drugs against COVID-19. Drug Discov Today. 2021;26(12):2800–2815. doi:10.1016/j.drudis.2021.07.026
   PubMed Web of Science ®Google Scholar
• Goyal M, Tewatia N, Vashisht H, Jain R, Kumar S. Novel Corona virus (COVID-19); Global efforts and effective investigational medicines: a review. J Infect Public Health. 2021;14(7):910–921. doi:10.1016/j.jiph.2021.04.011
   PubMed Web of Science ®Google Scholar
• Malek RJ, Bill CA, Vines CM. Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. Biomed Pharmacother. 2021;144(August):112276. doi:10.1016/j.biopha.2021.112276
   PubMedGoogle Scholar
• WHO Solidarity Trial Consortium. Repurposed antiviral drugs for covid-19 — interim who solidarity trial results. N Engl J Med. 2021;384(6):497–511. doi:10.1056/nejmoa2023184
   PubMed Web of Science ®Google Scholar
• Kmietowicz Z. Covid-19: WHO recommends baricitinib and sotrovimab to treat patients. BMJ. 2022;o97. doi:10.1136/bmj.o97
   PubMedGoogle Scholar
• Lamontagne F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent covid-19. BMJ. 2021:372. doi:10.1136/bmj.n526
   Google Scholar
• Rehman MU, Abdullah KF, Niaz K. Introduction to natural products analysis. Recent Adv Nat Prod Anal. 2020;3–15. doi:10.1016/B978-0-12-816455-6.00001-9
   Google Scholar
• Atanasov AG, Zotchev SB, Dirsch VM, et al. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–216. doi:10.1038/s41573-020-00114-z
   PubMed Web of Science ®Google Scholar
• Panikar S, Shoba G, Arun M, et al. Essential oils as an effective alternative for the treatment of COVID-19: molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. J Infect Public Health. 2021;14(5):601–610. doi:10.1016/j.jiph.2020.12.037
   PubMed Web of Science ®Google Scholar
• Aucoin M, Cardozo V, McLaren MD, et al. A systematic review on the effects of Echinacea supplementation on cytokine levels: is there a role in COVID-19? Metab Open. 2021;11:100115. doi:10.1016/j.metop.2021.100115
   PubMedGoogle Scholar
• Nagoor Meeran MF, Javed H, Sharma C, et al. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon. 2021;7(2):e05990. doi:10.1016/j.heliyon.2021.e05990
   PubMed Web of Science ®Google Scholar
• Das K. Herbal plants as immunity modulators against COVID-19: a primary preventive measure during home quarantine. J Herb Med. 2022;32:100501. doi:10.1016/j.hermed.2021.100501
   PubMed Web of Science ®Google Scholar
• Zhang D, Hamdoun S, Chen R, et al. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry. Pharmacol Res. 2021;172:105820. doi:10.1016/j.phrs.2021.105820
   PubMed Web of Science ®Google Scholar
• Omrani M, Keshavarz M, Nejad Ebrahimi S, et al. Potential natural products against respiratory viruses: a perspective to develop anti-COVID-19 medicines. Front Pharmacol. 2021;11. doi:10.3389/fphar.2020.586993
   PubMed Web of Science ®Google Scholar
• Kumar A, Choudhir G, Shukla SK, et al. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. J Biomol Struct Dyn. 2021;39(10):3760–3770. doi:10.1080/07391102.2020.1772112
   PubMed Web of Science ®Google Scholar
• Gyebi GA, Ogunro OB, Adegunloye AP, Ogunyemi OM, Afolabi SO. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants. J Biomol Struct Dyn. 2021;39(9):3396–3408. doi:10.1080/07391102.2020.1764868
   PubMed Web of Science ®Google Scholar
• Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761. doi:10.1016/j.phrs.2020.104761
   PubMed Web of Science ®Google Scholar
• Akinlalu AO, Chamundi A, Yakumbur DT, et al. Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: an in silico study. Sci Afr. 2021;13:e00845. doi:10.1016/j.sciaf.2021.e00845
   PubMedGoogle Scholar
• Jain S, Kumar P, Vyas RK, Pandit P, Dalai AK. Occurrence and removal of antiviral drugs in environment: a review. Water Air Soil Pollut. 2013;224(2). doi:10.1007/s11270-012-1410-3
   Web of Science ®Google Scholar
• Srivastava K, Singh MK. Drug repurposing in COVID-19: a review with past, present and future. Metab Open. 2021;12:100121. doi:10.1016/j.metop.2021.100121
   PubMedGoogle Scholar
• Tichauer JE, Soto D, Andresen M. Characterization of the modulatory effect of hydroxychloroquine on ACE2 Activity: new insights in relation to COVID-19. Biomed Res Int. 2021;2021:1–5. doi:10.1155/2021/6614000
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:1–10. doi:10.1186/1743-422X-2-69
   PubMed Web of Science ®Google Scholar
• Alsuwaidan S, Memish ZA, Alaklobi F, Khan K, Alajami HN. The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study. Ann Med Surg. 2021;70:102867. doi:10.1016/j.amsu.2021.102867
   PubMed Web of Science ®Google Scholar
• Oriol M, Marc C-M, Maria U. Hydroxychloroquine for early treatment of adults with mild covid-19: a randomized- controlled trial. Clin Infect Dis. 2020;54(650):1–54.
   Google Scholar
• Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: a Randomized Trial. Ann Intern Med. 2020;173(8):623–631. doi:10.7326/M20-4207
   PubMed Web of Science ®Google Scholar
• Kamstrup P, Sivapalan P, Eklöf J, et al. Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: a cohort study. Int J Infect Dis. 2021;108:370–376. doi:10.1016/j.ijid.2021.05.076
   PubMed Web of Science ®Google Scholar
• Rentsch CT, DeVito NJ, MacKenna B, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19–e27. doi:10.1016/S2665-9913(20)30378-7
   PubMedGoogle Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383(21):2041–2052. doi:10.1056/nejmoa2019014
   PubMed Web of Science ®Google Scholar
• Lamback EB, de Oliveira MA, Haddad AF, et al. Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. Brazilian J Infect Dis. 2021;25(2):1–6. doi:10.1016/j.bjid.2021.101549
   Web of Science ®Google Scholar
• Gupta S, Dixit PK, Ghana P, et al. Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection. Med J Armed Forces India. 2021;77:S305–S311. doi:10.1016/j.mjafi.2021.02.007
   PubMedGoogle Scholar
• Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect. 2021;43:100915. doi:10.1016/j.nmni.2021.100915
   PubMed Web of Science ®Google Scholar
• Chivese T, Musa OAH, Hindy G, et al. Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis. Travel Med Infect Dis. 2021;43(July):102135. doi:10.1016/j.tmaid.2021.102135
   PubMedGoogle Scholar
• Das S, Ramachandran AK, Birangal SR, Akbar S, Ahmed B, Joseph A. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: a comprehensive review. Med Drug Discov. 2021;10:100085. doi:10.1016/j.medidd.2021.100085
   PubMedGoogle Scholar
• Zapata-Cardona MI, Flórez-Álvarez L, Zapata-Builes W, et al. Atorvastatin effectively inhibits ancestral and two emerging variants of SARS-CoV-2 in vitro. Front Microbiol. 2022;13(March). doi:10.3389/fmicb.2022.721103
   PubMedGoogle Scholar
• Marín-Palma D, Tabares-Guevara JH, Zapata-Cardona MI, et al. Curcumin inhibits in vitro sars-cov-2 infection in Vero E6 cells through multiple antiviral mechanisms. Molecules. 2021;26(22):1–17. doi:10.3390/molecules26226900
   Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis. 2020;2:1–25.
   Google Scholar
• Yepes-Perez AF, Herrera-Calderón O, Oliveros CA, et al. The Hydroalcoholic Extract of Uncaria tomentosa (Cat’s Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Vitro. Evidence-Based Complement Altern Med. 2021;2021:1–11. doi:10.1155/2021/6679761
   Web of Science ®Google Scholar
• U.S Food and Drug Administration (FDA). Memorandum explaining basis for revocation of emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate. FDA site; 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed December 18, 2023.
   Google Scholar
• U.S Food and Drug Administration (FDA). FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems; 2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. Accessed December 18, 2023.
   Google Scholar
• Kinobe RT, Owens L. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin’s possible mode of action against SARS-CoV-2. Fundam Clin Pharmacol. 2021;35(2):260–276. doi:10.1111/fcp.12644
   PubMed Web of Science ®Google Scholar
• Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760. doi:10.1016/J.ANTIVIRAL.2020.104760
   PubMed Web of Science ®Google Scholar
• Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α / β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Bioch J. 2012;856:851–856. doi:10.1042/BJ20120150
   Google Scholar
• Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In vivo. 2020;34(5):3023–3026. doi:10.21873/invivo.12134
   PubMed Web of Science ®Google Scholar
• Ahmed S, Mahbubul M, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Biomed Biotechnol Res J. 2020;21(January):1–4. doi:10.21203/rs.3.rs-317485/v1
   Google Scholar
• Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021;49(5):030006052110135. doi:10.1177/03000605211013550
   Web of Science ®Google Scholar
• Okumuş N, Demirtürk N, Çetinkaya RA, et al. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21(1):1–11. doi:10.1186/s12879-021-06104-9
   PubMed Web of Science ®Google Scholar
• Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials: ivermectin and COVID-19. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102186. doi:10.1016/j.dsx.2021.102186
   PubMed Web of Science ®Google Scholar
• Mansour SM, Shamma RN, Ahmed KA, et al. Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: a preclinical tolerance study. Int Immunopharmacol. 2021;99(1):108004. doi:10.1016/j.intimp.2021.108004
   PubMedGoogle Scholar
• Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. EClinicalMedicine. 2021;37. doi:10.1016/j.eclinm.2021.100959
   PubMedGoogle Scholar
• López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426–1435. doi:10.1001/jama.2021.3071
   PubMed Web of Science ®Google Scholar
• Reis G, Silva EASM, Silva DCM, et al. Effect of early treatment with ivermectin among patients with covid-19. N Engl J Med. 2022;386(18):1721–1731. doi:10.1056/NEJMoa2115869
   PubMed Web of Science ®Google Scholar
• Calello DP, Kazzi Z, Stolbach A. American College of Medical Toxicology (ACMT) Cautions Against Off-Label Prescribing of Ivermectin for the Prevention or Treatment of COVID-19. J Med Toxicol. 2022;18(1):69–70. doi:10.1007/s13181-021-00866-z
   PubMed Web of Science ®Google Scholar
• CDC Health Alert Network. CDC HEALTH ADVISORY. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19; 2021.
   Google Scholar
• Baudou E, Lespine A, Durrieu G, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020;69(1):787–789.
   Google Scholar
• Ivermectina: cómo la falsa ciencia inventó un fármaco “milagroso” contra la covid-19 [Ivermectin: how false science invented a “miracle” drug against COVID-19]. BBC News Mundo. Available from: https://www.bbc.com/mundo/noticias-58828993. Accessed January 24, 2022
   Google Scholar
• Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns | medical research | the Guardian. Available from: https://www.theguardian.com/science/2021/jul/16/huge-study-supporting-ivermectin-as-covid-treatment-withdrawn-over-ethical-concerns. Accessed January 24, 2022
   Google Scholar
• FDA. Why you should not use ivermectin to treat or prevent COVID-19. Available from: https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19. Accessed May 31, 2022.
   Google Scholar
• Sallard E, Lescure F-X, Burdet C, Guedj J, Yazdan Yazdanpanah NP-S. Repurposed prophylaxis strategies for COVID-19: a review. medRxiv. 2020;600:2020–2025.
   Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. J Antibiot. 2022;75(2):60–71. doi:10.1038/s41429-021-00491-6
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178(January):104787. doi:10.1016/j.antiviral.2020.104787
   PubMedGoogle Scholar
• Yadav R, Imran M, Dhamija P, Suchal K, Handu S. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2. J Biomol Struct Dyn. 2021;39(12):4433–4448. doi:10.1080/07391102.2020.1778536
   PubMed Web of Science ®Google Scholar
• Dallocchio RN, Dessì A, De Vito A, Delogu G, Serra PA, Madeddu G. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Eur Rev Med Pharmacol Sci. 2021;25(5):2435–2448. doi:10.26355/eurrev_202103_25285
   PubMed Web of Science ®Google Scholar
• Taylor K, Fritz K, Parmar M. Lamivudine. Kucers use antibiot a clin rev antibacterial, antifung antiparasit antivir drugs; 2021:3729–3754. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559252/. Accessed September 8, 2021
   Google Scholar
• Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother. 2020;131:110668. doi:10.1016/j.biopha.2020.110668
   PubMed Web of Science ®Google Scholar
• Fadaka AO, Aruleba RT, Sibuyi NRS, Klein A, Madiehe AM, Meyer M. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach. J Biomol Struct Dyn. 2020;1(1):1–13. doi:10.1080/07391102.2020.1847197
   Google Scholar
• Barreto RG, Brites C. Low frequency of hypersensitivity reactions to Abacavir in HIV infected patients in a referral center in Bahia, Brazil. Brazilian J Infect Dis. 2019;23(4):268–270. doi:10.1016/j.bjid.2019.06.003
   PubMed Web of Science ®Google Scholar
• Chien M, Anderson TK, Jockusch S, et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res. 2020;19(11):4690–4697. doi:10.1021/acs.jproteome.0c00392
   PubMed Web of Science ®Google Scholar
• Quo R, De Clercq E. Remdesivir: quo vadis? Biochem Pharmacol. 2021;193:114800.
   PubMed Web of Science ®Google Scholar
• Ribavirin EAA, Remdesivir S. Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592. doi:10.1016/J.LFS.2020.117592
   PubMed Web of Science ®Google Scholar
• Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784–790. doi:10.1016/j.csbj.2020.03.025
   PubMed Web of Science ®Google Scholar
• Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Hear J Cardiovasc Pharmacother. 2020;6(4):258–259. doi:10.1093/EHJCVP/PVAA042
   PubMed Web of Science ®Google Scholar
• Gonzale SM, Aguilar-Jimenez W, Trujillo-Gil E, et al. Vitamin D treatment of peripheral blood mononuclear cells modulated immune activation and reduced susceptibility to HIV-1 infection of CD4+ T lymphocytes. PLoS One. 2019;14(9):1–15. doi:10.1371/journal.pone.0222878
   Web of Science ®Google Scholar
• Edwards Z, Ingold CJ, Azmat CE. Zidovudine. Kucers use antibiot a clin rev antibacterial, antifung antiparasit antivir drugs; 2021:3657–3697. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554419/. Accessed September 8, 2021
   Google Scholar
• Ju J, Li X, Kumar S, et al. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect. 2020;8(6):1–9. doi:10.1002/prp2.674
   Web of Science ®Google Scholar
• Zapata-Cardona MI, Florez-Alvarez L, Guerra-Sandoval AL, et al. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: a drug repurposing approach. AIMS Microbiol. 2023;9(1):20–40. doi:10.3934/microbiol.2023002
   PubMed Web of Science ®Google Scholar
• García-Trejo JJ, Ortega R, Zarco-Zavala M. Putative repurposing of lamivudine, a nucleoside/nucleotide analogue and antiretroviral to improve the outcome of cancer and COVID-19 patients. Front Oncol. 2021;11:1–17. doi:10.3389/fonc.2021.664794
   Web of Science ®Google Scholar
• Saxena RK, Samad AA, Khan UR, et al. Assessment of prevalence of SARS-CoV-2 Infection in patients on anti- HBV (lamivudine) treatment: a questionnaire based survey. IP Int J Med Microbiol Trop Dis. 2021;7(7):10–8231. doi:10.18231/j.ijmmtd.2021.005
   Google Scholar
• Jockusch S, Tao C, Li X, Anderson TK, Chien M. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res. 2020;180:104857.
   PubMed Web of Science ®Google Scholar
• Tomić D, Davidović D, Szasz A, et al. The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus. Inf Med. 2021;23:100529.
   Google Scholar
• Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med. 2020;173(7):536–541. doi:10.7326/M20-3689
   PubMed Web of Science ®Google Scholar
• Alshaeri HK, Natto ZS. A contemporary look at COVID-19 medications: available and potentially effective drugs. Eur Rev Med Pharmacol Sci. 2020;24(17):9188–9195. doi:10.26355/eurrev_202009_22870
   PubMed Web of Science ®Google Scholar
• Kickbusch I, Leung G, Briand S, et al. WHO R&D Blueprint Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. Euro Surveill. 2020;25(January):709–710. doi:10.1046/j.1466-7657.2000.00027
   Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/nejmoa2001282
   PubMed Web of Science ®Google Scholar
• Cheng CY, Lee YL, Chen CP, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020;53(3):488–492. doi:10.1016/j.jmii.2020.03.032
   PubMedGoogle Scholar
• Ader F, Peiffer-smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir / ritonavir, lopinavir / ritonavir plus IFN- b −1a and hydroxychloroquine in hospitalized patients with COVID-19, on behalf of the DisCoVeRy study. Clin Microbiol Infect. 2021;27(12):1826–1837. doi:10.1016/j.cmi.2021.05.020
   PubMed Web of Science ®Google Scholar
• Arabi YM, Gordon AC, Derde LPG, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47(8):867–886. doi:10.1007/s00134-021-06448-5
   PubMed Web of Science ®Google Scholar
• Reis G, Moreira Silva EADS, Medeiros Silva DC, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4(4):1–14. doi:10.1001/jamanetworkopen.2021.6468
   Web of Science ®Google Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198(January):10–12. doi:10.1016/j.antiviral.2022.105252
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — final Report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/nejmoa2007764
   PubMed Web of Science ®Google Scholar
• Olender SA, Perez KK, Go AS, et al. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. 2021;73(11):E4166–E4174. doi:10.1093/cid/ciaa1041
   PubMed Web of Science ®Google Scholar
• Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. EuropJ Pharmacol. 2021;897:173926.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305–315. doi:10.1056/nejmoa2116846
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. Effect of tenofovir disoproxil fumarate and emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial. eClinicalMedicine. 2021;38. doi:10.1016/j.eclinm.2021.100993
   PubMedGoogle Scholar
• Park S, Yu K, Kim Y, et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBIO. 2020;11(3):1–10. doi:10.1186/s13287-019-1471-y
   Web of Science ®Google Scholar
• Vos AG, Venter WDF Toxicidad cardiovascular de la terapia antirretroviral contemporánea [Cardiovascular toxicity of contemporary antiretroviral therapy]. Available from: https://pubmed.ncbi.nlm.nih.gov/34545036/. Accessed September 23, 2021
   Google Scholar
• Panche A, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5. doi:10.1017/jns.2016.41
   PubMedGoogle Scholar
• Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099. doi:10.1111/jth.14817
   PubMed Web of Science ®Google Scholar
• Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinic. JAMA. 2021;325(16):1620–1630. doi:10.1001/jama.2021.4152
   PubMed Web of Science ®Google Scholar
• Lopes RD, Gabriel P, De BM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253–2263. doi:10.1016/S0140-6736(21)01203-4
   PubMed Web of Science ®Google Scholar
• Jonmarker S, Hollenberg J, Dahlberg M, et al. Dosing of thromboprophylaxis and mortality in critically ill COVID –19 patients. Crit Care. 2020:1–10. doi:10.1186/s13054-020-03375-7
   PubMedGoogle Scholar
• Barnes GD, Burnett A, Allen A, et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2022;54(2):197–210. doi:10.1007/s11239-022-02643-3
   PubMed Web of Science ®Google Scholar
• Gabara C, Solarat B, Castro P, Fern S. Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients. Med Inten. 2023;47(1):1–8. doi:10.1016/j.medin.2021.07.004
   Web of Science ®Google Scholar
• Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060–2072. doi:10.1016/j.jacc.2020.08.070
   PubMed Web of Science ®Google Scholar
• Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19–related illness. J Thromb Haemost. 2020;18(11):3099–3105. doi:10.1111/jth.15073
   PubMed Web of Science ®Google Scholar
• The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N Engl J Med. 2021;385(9):777–789. doi:10.1056/nejmoa2103417
   PubMed Web of Science ®Google Scholar
• Rey JR, Luis Merino J, Iniesta ÁM, et al. Influencia del tratamiento con estatinas en una cohorte de pacientes ingresados por COVID-19. Med Clin. 2021. doi:10.1016/j.medcli.2021.07.003
   Google Scholar
• Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24(1):4–5. doi:10.1186/s13054-020-03154-4
   PubMed Web of Science ®Google Scholar
• Santosa A, Franzén S, Nåtman J, Wettermark B, Parmryd I, Nyberg F. Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study. Sci Rep. 2022;12(1):1–9. doi:10.1038/s41598-022-16357-2
   PubMed Web of Science ®Google Scholar
• Daniels LB, Ren J, Kumar K, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association’s COVID-19 cardiovascular disease registry. PLoS One. 2021;16(7 July):1–16. doi:10.1371/journal.pone.0254635
   Web of Science ®Google Scholar
• Antonazzo IC, Fornari C, Rozza D, et al. Statins use in patients with cardiovascular diseases and COVID-19 Outcomes: an Italian population-based cohort study. J Clin Med. 2022;11(24):7492. doi:10.3390/jcm11247492
   PubMed Web of Science ®Google Scholar
• Barge-caballero E, Marcos-rodríguez PJ, Domenech-garcía N, Mu J. Survival impact of previous statin therapy in patients hospitalized with COVID-19. Med Clín. 2023;160(1):1–9.
   PubMed Web of Science ®Google Scholar
• Yetmar ZA, Challener DW, Tleyjeh IM, et al. Association between chronic statin use and 30-day mortality in hospitalized patients with COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):442–446. doi:10.1016/j.mayocpiqo.2021.02.002
   PubMedGoogle Scholar
• Zapata-Cardona MI, Flórez-Álvarez L, Zapata-Builes W, Guerra-Sandoval AL, Guerra-Almonacid CM, Hincapié-García J. Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2 in vitro. bioRxiv. 2021;2021:1. doi:10.1101/2021.03.01.433498
   Google Scholar
• Glorieux FH, Pettifor JM. Vitamin D/dietary calcium deficiency rickets and pseudo-vitamin D deficiency rickets. Bonekey Rep. 2014;3(March):1–6. doi:10.1038/bonekey.2014.19
   Google Scholar
• Lung BE, Mowery ML, Calcitriol KDEE. xPharm Compr Pharmacol Ref; 2021:1–5. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526025/. Accessed September 10, 2021
   Google Scholar
• Sadeghzadeh M, Khoshnevisasl P, Motamed N, Faghfouri L. The serum vitamin D levels in children with urinary tract infection: a case–control study. New Microbes New Infect. 2021;43:100911. doi:10.1016/j.nmni.2021.100911
   PubMed Web of Science ®Google Scholar
• Nimavat N, Singh S, Singh P, Singh SK, Sinha N. Vitamin D deficiency and COVID-19: a case-control study at a tertiary care hospital in India. Ann Med Surg. 2021;68:102661. doi:10.1016/j.amsu.2021.102661
   PubMed Web of Science ®Google Scholar
• Pereira M, Dantas Damascena A, Galvão Azevedo LM, de Almeida Oliveira T, da Mota Santana J. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2020;1–9. doi:10.1080/10408398.2020.1841090
   Web of Science ®Google Scholar
• Annweiler C, Beaudenon M, Simon R, et al. Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: extension phase of the GERIA-COVID study. J Steroid Biochem Mol Biol. 2021;213(May):105958. doi:10.1016/j.jsbmb.2021.105958
   PubMedGoogle Scholar
• Nasiri M, Khodadadi J, Molaei S. Does vitamin D serum level affect prognosis of COVID-19 patients? Int J Infect Dis. 2021;107:264–267. doi:10.1016/j.ijid.2021.04.083
   PubMed Web of Science ®Google Scholar
• Elham AS, Azam K, Azam J, Mostafa L, Nasrin B, Marzieh N. Serum vitamin D, calcium, and zinc levels in patients with COVID-19. Clin Nutr ESPEN. 2021;43:276–282. doi:10.1016/j.clnesp.2021.03.040
   PubMed Web of Science ®Google Scholar
• Diaz-Curiel M, Cabello A, Arboiro-Pinel R, et al. The relationship between 25(OH) vitamin D levels and COVID-19 onset and disease course in Spanish patients. J Steroid Biochem Mol Biol. 2021;212(January):6–11. doi:10.1016/j.jsbmb.2021.105928
   Google Scholar
• Entrenas M, Manuel L, Costa E, Bouillon R, Francisco J. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751. doi:10.1016/j.jsbmb.2020.105751
   PubMed Web of Science ®Google Scholar
• Rawat D, Roy A, Maitra S, Shankar V, Khanna P, Baidya DK. Vitamin D supplementation and COVID-19 treatment: a systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102189. doi:10.1016/j.dsx.2021.102189
   PubMed Web of Science ®Google Scholar
• Güven M, Gültekin H. The effect of high-dose parenteral vitamin D3 on COVID-19-related inhospital mortality in critical COVID-19 patients during intensive care unit admission: an observational cohort study. Eur J Clin Nutr. 2021;75(9):1383–1388. doi:10.1038/s41430-021-00984-5
   PubMed Web of Science ®Google Scholar
• Shah K, Saxena D, Mavalankar D. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis. Qjm. 2021;114(3):175–181. doi:10.1093/qjmed/hcab009
   PubMed Web of Science ®Google Scholar
• Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014;4(1):24–35. doi:10.4103/2225-4110.124335
   PubMedGoogle Scholar
• Silveira D, Prieto-Garcia JM, Boylan F, et al. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Front Pharmacol. 2020;11:1–44. doi:10.3389/fphar.2020.581840
   PubMed Web of Science ®Google Scholar
• Marutescu L, Popa M, Saviuc C, Lazar V, Chifiriuc MC. Botanical pesticides with virucidal, bactericidal, and fungicidal activity. New Pestic Soil Sensors. 2017;311–335. doi:10.1016/B978-0-12-804299-1.00009-6
   Google Scholar
• Humayun F, Khan A, Ahmad S, et al. Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: a structural-dynamics data. Comput Biol Med. 2021:104714. doi:10.1016/j.compbiomed.2021.104714
   PubMed Web of Science ®Google Scholar
• Abebe EC, Ayele TM, Muche ZT, Dejenie TA. Neuropilin 1: a novel entry factor for sars-cov-2 infection and a potential therapeutic target. Biol Targets Ther. 2021;15:143–152. doi:10.2147/BTT.S307352
   PubMedGoogle Scholar
• Alhadrami HA, Burgio G, Thissera B, et al. Neoechinulin A as a Promising SARS-CoV-2 M pro Inhibitor: in vitro and in silico study showing the ability of simulations in discerning active from inactive enzyme inhibitors. Mar Drugs Artic. 2022;20(3):163. doi:10.3390/md20030163
   PubMed Web of Science ®Google Scholar
• Mahmoud DB, Ismail WM, Moatasim Y, et al. Delineating a potent antiviral activity of Cuphea ignea extract loaded nano-formulation against SARS-CoV-2: in silico and in vitro studies. J Drug Deliv Sci Technol. 2021;66:102845. doi:10.1016/j.jddst.2021.102845
   PubMed Web of Science ®Google Scholar
• Yang M, Wei J, Huang T, et al. Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells. Phyther Res. 2021;35(3):1127–1129. doi:10.1002/ptr.6916
   PubMed Web of Science ®Google Scholar
• Ter Ellen BM, Kumar ND, Bouma EM, et al. Resveratrol and pterostilbene inhibit sars-cov-2 replication in air–liquid interface cultured human primary bronchial epithelial cells. Viruses. 2021;13(7):1335. doi:10.3390/v13071335
   PubMed Web of Science ®Google Scholar
• Salminen W, Agbaje-williams M, Ajayi FO. A unique formulation of cardioprotective bio-actives: an overview of their safety profile. Medicines. 2019;6(4):107. doi:10.3390/medicines6040107
   Google Scholar
• Kemper C, Behnam D, Brothers S, et al. Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM). AAPS open. 2022;8(1):11. doi:10.1186/s41120-022-00058-1
   PubMedGoogle Scholar
• Suručić R, Maja T, Petković M, et al. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 Receptor: in silico and in vitro studies. Mol Cell Biochem. 2021;476(2):1179–1193. doi:10.1007/s11010-020-03981-7
   PubMedGoogle Scholar
• Kandeil A, Mostafa A, Kutkat O, et al. Bioactive polyphenolic compounds showing strong antiviral activities against severe acute respiratory syndrome coronavirus 2. Pathogens. 2021;10(6):758. doi:10.3390/pathogens10060758
   PubMed Web of Science ®Google Scholar
• Tirelli C, De Amici M, Albrici C, et al. Exploring the role of immune system and inflammatory cytokines in sars-cov-2 induced lung disease: a narrative review. Biology. 2023;12(2):177.
   PubMedGoogle Scholar
• Food E, Authority S. Refined exposure assessment for curcumin (E 100). EFSA J. 2014;12(10):1–43. doi:10.2903/j.efsa.2014.3876
   Google Scholar
• Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:4–7. doi:10.1186/1472-6882-6-10
   PubMedGoogle Scholar
• Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–6854. doi:10.1158/1078-0432.CCR-04-0744
   PubMed Web of Science ®Google Scholar
• Pancholi V, Smina TP, Kunnumakkara AB, Maliakel B, Krishnakumar IM. Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with a special reference to the recent hepatotoxic reports of curcumin supplements: a 90-days prospective study. Toxicol Rep. 2021;8(May):1255–1264. doi:10.1016/j.toxrep.2021.06.008
   PubMedGoogle Scholar
• Abian O, Ortega-alarcon D, Jimenez-alesanco A, Ceballos-laita L. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int J Biol Macromol. 2020;164:1693–1703. doi:10.1016/j.ijbiomac.2020.07.235
   PubMed Web of Science ®Google Scholar
• Bhowmik D, Nandi R, Prakash A, Kumar D. Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis. Heliyon. 2021;7:e06515. doi:10.1016/j.heliyon.2021.e06515
   PubMed Web of Science ®Google Scholar
• Saeedi-boroujeni A. Anti-inflammatory potential of Quercetin in COVID-19 treatment. J Inflamm. 2021;6:1–9.
   Google Scholar
• Miyamoto N, Izumi H, Miyamoto R, et al. Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway. Investig Ophthalmol Vis Sci. 2011;52(2):1055–1063. doi:10.1167/iovs.10-5777
   PubMed Web of Science ®Google Scholar
• Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11(1):1–12. doi:10.1038/s41467-020-18764-3
   PubMed Web of Science ®Google Scholar
• Carfora V, Spiniello G, Ricciolino R, et al. Anticoagulant treatment in COVID ‑ 19: a narrative review. J Thromb Thrombolysis. 2021;51(3):642–648. doi:10.1007/s11239-020-02242-0
   PubMed Web of Science ®Google Scholar
• Shohan M, Nashibi R, Mahmoudian-sani M. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: a randomized controlled trial. Eur. J. Pharmacol. 2022;914:174615.
   PubMed Web of Science ®Google Scholar
• Belhassan A, Zaki H, Chtita S, et al. Camphor, artemisinin and sumac phytochemicals as inhibitors against COVID-19: computational approach. Comput Biol Med. 2021;136:104758. doi:10.1016/j.compbiomed.2021.104758
   PubMed Web of Science ®Google Scholar
• Li L, Ma L, Hu Y, et al. Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease. Phytochemistry. 2022;193(July 2021):112984. doi:10.1016/j.phytochem.2021.112984
   PubMedGoogle Scholar
• Xiao T, Cui M, Zheng C, et al. Myricetin Inhibits SARS-CoV-2 viral replication by targeting mpro and ameliorates pulmonary inflammation. Front Pharmacol. 2021;12:1–9. doi:10.3389/fphar.2021.669642
   Web of Science ®Google Scholar
• Wen CC, Kuo YH, Jan JT, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087–4095. doi:10.1021/jm070295s
   PubMed Web of Science ®Google Scholar
• Alhadrami HA, Sayed AM, Sharif AM, Azhar EI, Rateb ME. Olive-derived triterpenes suppress SARS COV-2 main protease: a promising scaffold for future therapeutics. Molecules. 2021;26(9):2654.
   PubMed Web of Science ®Google Scholar
• Carino A, Moraca F, Fiorillo B, et al. Hijacking SARS-CoV-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on the receptor binding domain. Front Chem. 2020;8(October):1–15. doi:10.3389/fchem.2020.572885
   PubMedGoogle Scholar
• Pasquereau S, Nehme Z, Haidar Ahmad S, et al. Resveratrol inhibits hcov-229e and sars-cov-2 coronavirus replication in vitro. Viruses. 2021;13(2):1–11. doi:10.3390/v13020354
   Web of Science ®Google Scholar
• Zhang B, Swamy S, Balijepalli S, et al. Direct pulmonary delivery of solubilized curcumin reduces severity of lethal pneumonia. FASEB J. 2019;33(12):13294–13309. doi:10.1096/fj.201901047RR
   PubMed Web of Science ®Google Scholar
• Cheng F-J, Huynh T-K, Yang C-S, et al. Hesperidin Is a Potential Inhibitor against. Nutrients. 2021:13. doi:10.3390/nu14010013
   PubMed Web of Science ®Google Scholar
• Sofowora A, Ogunbodede E, Onayade A. The role and place of medicinal plants in the strategies for disease prevention. Afr J Tradit Complement Altern Med. 2013;10(5):210–229. doi:10.4314/ajtcam.v10i5.2
   PubMedGoogle Scholar
• Luo L, Jiang J, Wang C, et al. Analysis on herbal medicines utilized for treatment of COVID-19. Acta Pharm Sin B. 2020;10(7):1192–1204. doi:10.1016/j.apsb.2020.05.007
   PubMed Web of Science ®Google Scholar
• Valoyes DC, Palacios Palacios L. Patrones de uso de las plantas medicinales en el Chocó y Cauca (Colombia) [Patterns of use of medicinal plants in Chocó and Cauca (Colombia)]. Cienc en Desarro. 2020;11(2):85–96 Spanish . doi:10.19053/01217488.v11.n2.2020.10583
   Google Scholar
• Flórez-álvarez L, Martínez-Moreno J, Zapata-Cardona MI, Galeano E, Alzate-Guarin F, Zapata W. In vitro antiviral activity against SARS-CoV-2 of plant extracts used in Colombian traditional medicine. Vitae. 2022;29(1):1–11. doi:10.17533/udea.vitae.v29n1a347854
   Google Scholar
• Jaimes-Gualdron T, Florez-Alvarez L, Zapata-Cardona MI, Rojano BA, Rugeles MT, Zapata-Builes W. Corozo (Bactris guineensis) fruit extract has antiviral activity in vitro against SARS-CoV-2. Funct Foods Health Dis. 2022;12(9):534–546. doi:10.31989/ffhd.v12i9.918
   Web of Science ®Google Scholar
• Urueña C, Ballesteros-Ramírez R, Gomez-Cadena A, et al. Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et). Front Med. 2022;9:991873. doi:10.3389/fmed.2022.991873
   Google Scholar